Delving into the Latest Updates on APD-209 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ADE CTP-12-001, APD 209

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsInfectious DiseasesEye Diseases+ [1]

Active Indication-

Inactive Indication

Adenoviridae InfectionsAdvanced cancerCachexia+ [1]

Originator Organization

Adenovir Pharma AB

Active Organization-

Inactive Organization

Adenovir Pharma AB

Acacia Pharma Ltd.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC54H95N3O16

InChIKeyVRJMVFQLUBTBKF-HBJHFNNESA-N

CAS Registry1261156-82-4

A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC. The aims of the study are to investigate the therapeutic efficacy of APD-209 Eye drops as measured by adenoviral load, time to viral eradication, clinical resolution of EKC (objective and subjective assessments), presence of opacities, visual acuity and frequency of second eye infections, and to assess the safety and tolerability of APD-209 Eye drops in EKC infected eyes.

Start Date01 Nov 2013

Sponsor / Collaborator

Adenovir Pharma AB

[+1]

NCT00895726

/ CompletedPhase 2

Open-Label, Pilot Phase I/II Study of the Efficacy and Safety of APD209 in Patients With Cachexia and Advanced Malignancy

Primary Objective:
To assess the efficacy of APD209 in adult patients with active cachexia associated with advanced malignancy and not caused by simple starvation.
Secondary Objective:
To assess the safety of APD209 in patients with advanced malignancy and active cachexia.

Start Date01 Mar 2009

Sponsor / Collaborator

Acacia Pharma Ltd.

100 Clinical Results associated with APD-209

Login to view more data

100 Translational Medicine associated with APD-209

Login to view more data

100 Patents (Medical) associated with APD-209

Login to view more data

100 Deals associated with APD-209

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Keratoconjunctivitis	Phase 2	Germany	Adenovir Pharma AB	01 Nov 2013
Keratoconjunctivitis	Phase 2	Poland	Adenovir Pharma AB	01 Nov 2013
Keratoconjunctivitis	Phase 2	Sweden	Adenovir Pharma AB	01 Nov 2013
Advanced cancer	Phase 2	United Kingdom	Acacia Pharma Ltd.	01 Mar 2009
Cachexia	Phase 2	United Kingdom	Acacia Pharma Ltd.	01 Mar 2009
Adenoviridae Infections	Phase 2	-	Adenovir Pharma AB	-